Research & Development News Channel

Study tracks COVID-19 antibodies over time

The antibodies generated by Pfizer's COVID-19 vaccine rise more slowly and decline more quickly than those generated by the Moderna vaccine, according to a new study from UVA Health. The study also finds that older recipients of the Pfizer vaccine generated fewer antibodies than did younger recipients - but this wasn't the case for Moderna, where age did not appear to be a factor.

New COVID-19 nasal spray outperforms current antibody treatments in mice

A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I human clinical trials to treat COVID-19.

Designed computationally and refined in the laboratory, the new protein therapies thwarted infection by interfering with the virus' ability to enter cells.

New approach for delivery of anti-HIV antibody therapy shows promise in phase I clinical trial

Since the first reports of HIV infection in the early 1980s, multiple clinical trials have tested potential vaccines against the virus, but unfortunately, HIV has numerous defense mechanisms that prevent a person's immune system from mounting an effective response following HIV vaccination. An alternative anti-HIV strategy called Vectored ImmunoProphylaxis (VIP) designed by researchers at the

Fighting viruses is as easy as breathing

The average person will take more than 600 million breaths over the course of their life. Every breath stretches the lungs’ tissues with each inhale and relaxes them with each exhale. The mere motions of breathing are known to influence vital functions of the lungs, including their development in babies, the production of air-exchange-enhancing fluid on their inner surfaces, and maintenance of healthy tissue structure.

Researchers look to licorice for promising cancer treatments

Licorice is more than a candy people either love or hate - it may play a role in preventing or treating certain types of cancer, according to researchers at the University of Illinois Chicago.

Gnanasekar Munirathinam and his research team are studying substances derived from the licorice plant Glycyrrhiza glabra to determine if they could be used to prevent or stop the growth of prostate cancer.

Cancer repair mechanism could be potential drug target

While cancer therapies targeting specific genes or disease pathways have extended lives, they can also lead to highly resistant tumors when small reservoirs of cancer cells survive treatment, grow, and spread.

Searching for ways to extend the survival benefit of targeted therapies, a team led by researchers at the Duke Cancer Institute identified a potential new tactic to disrupt the repair mechanism that cancer cells use after treatment, blunting their ability to regenerate.

NIH begins clinical trial evaluating second COVID-19 booster shots in adults

A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. The trial aims to understand if different vaccine regimens - prototype and variant vaccines alone and in combinations - can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot.

Research & Development News

Study tracks COVID-19 antibodies over time

New COVID-19 nasal spray outperforms current antibody treatments in mice

New approach for delivery of anti-HIV antibody therapy shows promise in phase I clinical trial

Fighting viruses is as easy as breathing

Researchers look to licorice for promising cancer treatments

Cancer repair mechanism could be potential drug target

NIH begins clinical trial evaluating second COVID-19 booster shots in adults

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs